Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: paclitaxel
Procedure: conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2017-07-31

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 82

Registration Number: NCT00006110

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: CHOP regimen
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Radiation: radiation therapy
Drug: vincristine sulfate

First Posted Date: 2003-01-27

Last Posted Date: 2021-05-18

Lead Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group

Target Recruit Count: 1506

Registration Number: NCT00052936

Locations: 🇩🇪
Onkologische Schwerpunktpraxis, Hildesheim, Germany
🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
🇩🇪
General Hospital, Celle, Germany

and more 160 locations

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2019-08-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 393

Registration Number: NCT00004228

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States

and more 172 locations

Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Scotland and Newcastle Lymphoma Group

Registration Number: NCT00003815

Locations: 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: dexamethasone
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: methotrexate
Drug: pegaspargase
Drug: doxorubicin hydrochloride
Drug: mercaptopurine
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-02-23

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 3054

Registration Number: NCT00005945

Locations: 🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States

and more 127 locations

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Phase 2

Withdrawn

Conditions: Retinoblastoma
Brain and Central Nervous System Tumors
Neuroblastoma
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-12-03

Lead Sponsor: NYU Langone Health

Registration Number: NCT00003273

Locations: 🇺🇸
Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸
State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States

and more 16 locations

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: filgrastim
Drug: recombinant interferon alfa
Procedure: peripheral blood stem cell transplantation
Procedure: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 22

Registration Number: NCT00005984

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma
Plasma Cell Neoplasm

Interventions: Biological: filgrastim
Biological: CD34+ cells
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: melphalan
Drug: methotrexate
Drug: tacrolimus

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 60

Registration Number: NCT00028600

Locations: 🇺🇸
Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
🇺🇸
Union Hospital Cancer Program at Union Hospital, Elkton MD, Maryland, United States
🇺🇸
CCOP - Christiana Care Health Services, Newark, Delaware, United States

and more 12 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy